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Although recent studies provide evidence for a common genetic basis between complex traits and Mendelian disorders, a thorough
quantification of their overlap in a phenotype-specific manner remains elusive. Here, we have quantified the overlap of genes identified
through large-scale genome-wide association studies (GWASs) for 62 complex traits and diseases with genes containing mutations
known to cause 20 broad categories of Mendelian disorders. We identified a significant enrichment of genes linked to phenotypically
matched Mendelian disorders in GWAS gene sets; of the total 1,240 comparisons, a higher proportion of phenotypically matched or
related pairs (n ¼ 50 of 92 [54%]) than phenotypically unmatched pairs (n ¼ 27 of 1,148 [2%]) demonstrated significant overlap, con-
firming a phenotype-specific enrichment pattern. Further, we observed elevated GWAS effect sizes near genes linked to phenotypically
matched Mendelian disorders. Finally, we report examples of GWAS variants localized at the transcription start site or physically inter-
acting with the promoters of genes linked to phenotypically matched Mendelian disorders. Our results are consistent with the hypoth-
esis that genes that are disrupted inMendelian disorders are dysregulated by non-coding variants in complex traits and demonstrate how
leveraging findings from related Mendelian disorders and functional genomic datasets can prioritize genes that are putatively dysregu-
lated by local and distal non-coding GWAS variants.Introduction
Genetic architectures of human traits have traditionally
been classified into two major categories. Typically, com-
plex traits demonstrate polygenic architectures arising
from many low-effect common variants, whereas rare
traits tend to have high-effect monogenic determi-
nants.1 The underlying and practical distinction between
these classes has historically been based on the presence
of highly penetrant, rare, single-gene disruptive muta-
tions causing recognizable clinical syndromes and mono-
genic diseases (e.g., cystic fibrosis [MIM: 219700]2), and
the relative absence of such mutations in complex dis-
eases, such as diabetes and schizophrenia.3 Accumulating
evidence suggests that these two classes of phenotypes
might not be as biologically distinct as previously
thought.4 Multiple exceptions to the ‘‘common disease,
common variant’’ hypothesis1 have been identified for
complex traits5–7 and their molecular phenotypes,8–11
and Mendelian disorders have also been found to be
affected by multiple or common genetic variants.12–15
This suggests that there exists a spectrum of genetic
architectures rather than a dichotomous classification.
Accordingly, the monogenic forms of complex traits
(i.e., phenotypically matched Mendelian disorders) are
increasingly used as a starting point for identifying genes
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common variants, and copy-number variants linked to
Mendelian disorders and genetic determinants of complex
diseases and traits such as Parkinson disease (MIM:
68600),19 obesity,20 height,21 ototoxicity,22 and others.23
However, the overlap between each of these complex
traits and Mendelian disorders has been examined indi-
vidually with different metrics of overlap. In a large study
of patient medical records, Blair et al. identified system-
atic, significant comorbidities between Mendelian disor-
ders and complex diseases and found that association
signals from genome-wide association studies (GWASs)
for complex diseases were enriched in genomic regions
with known roles in comorbid Mendelian disorders, sug-
gesting a shared genetic basis.24 However, the study
focused on Mendelian disorders comorbid with complex
diseases in the same individual rather than examining
Mendelian disorders demonstrating phenotypes similar
to complex traits. Furthermore, advances in sequencing
technology have greatly expanded the phenotypic spec-
trum in known Mendelian syndromes, allowing for
deconstruction of syndromic diseases into component
medical phenotypes. As such, it is now possible to iden-
tify all the component-phenotype consequences of genes
linked to Mendelian disorders, allowing for greater resolu-
tion in identifying gene-phenotype relationships. How-
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advantage of this to identify genes linked to any related
component-phenotype regardless of the Mendelian disor-
der’s best-known or primary phenotype. Thus, a thorough
quantification of the overlap between genes associated
with complex traits and genes linked to Mendelian disor-
ders in a phenotype-specific manner remains elusive.
Given that the majority of GWASs for complex traits and
diseases have identified significant associations in non-cod-
ing genomic regions,25 we hypothesize that genes individ-
ually involved in Mendelian disease belong to the
biological pathway(s) shared by both complex and Mende-
lian disease. Specifically, we hypothesize that large-effect
coding variants disrupt individual genes and thus result
in severe phenotypes (i.e., Mendelian disorders), whereas
non-coding variants produce complex traits by collectively
dysregulating expression of these same genes, allowing for
nuanced or tissue-specific phenotypes. On the basis of
this hypothesis, we expect to identify an enrichment of
GWAS signal for a given complex trait near genes linked
to Mendelian disorders demonstrating similar phenotypes
but no enrichment near genes linked to Mendelian disor-
ders with phenotypes unrelated to the complex trait of
interest. To test this hypothesis, we defined ‘‘Mendelian dis-
order genes’’ as any genes linked to Mendelian disorders in
the Online Mendelian Inheritance in Man (OMIM) data-
base. We used the well-curated phenotypic breakdown of
Mendelian disorders in OMIM to identify subsets of these
genes linked to particular phenotypes (e.g., growth defects
or immune dysregulation) expressed as part of any Mende-
lian disorder. We then examined publicly available GWASs
across 62 complex traits (listed in Table 1 and detailed in
Table S1) to identify risk genes (here called GWAS gene
sets) for each complex trait and quantified the overlap be-
tween each GWAS gene set and 20 other sets of Mendelian
disorder genes for particular phenotypes (detailed in Tables
1 and S1). We found a consistent, significant, and specific
enrichment between GWAS gene sets for complex traits
andMendelian disorder genes for matched and related phe-
notypes (50 of 1,240 pairs; e.g., rheumatoid arthritis and
immune dysregulation), supporting our hypothesis of a
shared genetic basis between complex and Mendelian
forms of disease. In addition, we observed instances of
enrichment between GWAS gene sets for certain complex
traits and Mendelian disorder genes for unrelated pheno-
types (27 of 1,240 pairs; e.g., systemic lupus erythematosus
[SLE (MIM: 152700)] and mature-onset diabetes of the
young), suggestive of shared biological mechanisms yet to
be examined. Furthermore, we found an increase in average
effect size of GWAS variants near Mendelian disorder genes
for matched phenotypes, and we identified examples of
associated SNPs found directly at the transcription start
sites (TSSs) of these phenotypicallymatchedMendelian dis-
order genes as candidates for functional follow-up. Finally,
we report examples of significant body mass index (BMI)-
associated variants directly interacting with phenotypically
related Mendelian disorder genes CREBBP (MIM: 180849)
and CYP19A1 (MIM: 139300 and 613546) by using humanprimary white-adipocyte-specific Hi-C data.66 Leveraging
the growing body of well-curated phenotypic data from
studies of Mendelian disorders, we provide a phenotype-
driven approach to identifying genetic pathways shared
by Mendelian diseases and complex traits.Material and Methods
Gene Coordinates and Symbols
We downloaded gene-body coordinates (GRCh37/hg19, UCSC
Genes track) from the UCSC Table Browser67 (see Web Resources)
and specifically selected the gene symbol from the ‘‘knownGene’’
table, transcription start and end sites for each gene from the
‘‘knownCanonical’’ table, and the longest transcript from the
‘‘knownGene’’ table for genes where no entry or multiple entries
were listed in the ‘‘knownCanonical’’ table. We used these coordi-
nates for all analyses in our study. Because many genes have been
renamed over time, we standardized gene symbols across all ana-
lyses in our study by downloading a table of approved symbols,
previous symbols, and locus group for each gene from the
HUGO Gene Nomenclature Committee at the European Bioinfor-
matics Institute (HGNC) (see Web Resources) and renaming any
genes identified by previous symbols with approved gene symbols.
We restricted all analyses in our study to genes classified as pro-
tein-coding according to the HGNC locus group from chromo-
somes 1–22. These processing steps resulted in a final single set
of coordinates for 17,695 autosomal protein-coding genes (for
data access, see Web Resources).
Mendelian Disorder Genes and LoF-Intolerant Genes
To identify Mendelian disorder genes, we downloaded the OMIM
catalog and identified all genes linked to Mendelian disorders
satisfying the following criteria: (1) disorder is Mendelian and fully
penetrant, therefore excluding susceptibility phenotypes, and (2)
molecular basis of the Mendelian disorder is known (i.e., pheno-
type mapping key ¼ 3). We defined loss-of-function (LoF)-intol-
erant genes as all genes with greater than 90% probability of being
LoF intolerant according to the pLI score (>0.9) from the Exome
Aggregation Consortium (ExAC) Browser;68 this score is derived
from the number of observed versus expected LoF variants in a
given gene across approximately 60,000 healthy exomes.
Following the same restriction and gene symbol standardization
criteria described above resulted in a final set of 3,446 Mendelian
disorder genes and 2,978 LoF-intolerant genes.
Phenotype-Specific Mendelian Disorder Gene Sets
To identify subsets of Mendelian disorder genes linked to partic-
ular phenotypes, for each complex trait we curated a set of stan-
dardized clinical phenotype terms to describe the full range of
relevant Mendelian phenotypes. We used these terms to search
OMIM for all Mendelian disorders demonstrating these pheno-
types and then extracted the gene(s) linked to each Mendelian
disorder. We restricted gene-phenotype associations to those
satisfying criteria (1) and (2) described above and with the
following additional criteria: (3) gene-phenotype association
description does not contain ‘‘genome-wide association study’’
or other GWAS synonyms unless the description also contains
any of the terms ‘‘missense,’’ ‘‘nonsense,’’ ‘‘nonsynonymous,’’
or ‘‘frameshift’’ or the gene contains at least one pathogenic
or likely pathogenic allele in ClinVar. We include a full list of
Table 1. Complex Traits and Corresponding Mendelian Disorders
Complex Trait Abbreviation No. of GWAS Genes Matched Mendelian Disorder(s)
Celiac disease26 CEL 34 immune dysregulation
Crohn disease27 CD 239
Inflammatory bowel disease27 IBD 368
Ulcerative colitis28 UC 202
Primary biliary cirrhosis29 PBC 149
Rheumatoid arthritis (European)30 RA 297
Multiple sclerosis31 MS 160
Autism32 AUT 2 monogenic autism
Hemoglobin33 HB 89 hematologic disorders
Mean cell hemoglobin33 MCH 164
Mean cell hemoglobin concentration33 MCHC 12
Mean corpuscular volume33 MCV 180
Mean platelet volume28 MPV 102
Red blood cell count33 RBC 107
Systemic lupus erythematosus34 SLE 286
Birthweight35 BW 179 growth defects
Height36 HGT 2361
Femoral neck bone mineral density37 FN 58 bone and uric acid disorders
Forearm bone mineral density37 FA 8
Lumbar spine bone mineral density37 LS 67
Serum urate concentration38 URT 161
Packed cell volume33 PCV 53 disorders of platelet function
Platelet count28 PLT 134
Coronary artery disease39 CAD 132 cardiovascular disease
High-density lipoprotein40 HDL 464
Low-density lipoprotein40 LDL 370
Total cholesterol40 TC 500
Triglycerides40 TG 354
Hemoglobin A1C41 HBA 33 monogenic diabetes
Type 2 diabetes42 T2D 28
Age-related macular degeneration43 AMD 215 monogenic AMD
Age at menarche44 MNR 207 female reproductive disorders
Age at menopause45 MNP 316
Fasting glucose46 FG 39 insulin disorders
HOMA-B46 HMB 12
HOMA-IR46 HMIR 0
Micro-albuminuria47 MA 2 microalbumin disorders
Fasting insulin46 FI 23 mature-onset diabetes of the young
2 hr glucose48 2HG 2
Type 1 diabetes49 T1D 144
(Continued on next page)
Table 1. Continued
Complex Trait Abbreviation No. of GWAS Genes Matched Mendelian Disorder(s)
Alzheimer disease50 ALZ 58 neurologic disease
Anxiety disorders (case-control)51 ANXC 2
Anxiety disorders (factor score)51 ANXF 3
Major depressive disorder52 MDD 4
Depressive symptoms53 DS 10
Neuroticism53 NRT 82
Bipolar disorder54 BIP 8 psychiatric disease
Schizophrenia55 SCZ 479
Chronic kidney disease56 CKD 16 renal disorders
Glomerular filtration rate (creatinine)56 EGFR 162
Urine albumin-to-creatinine ratio47 UACR 2
Resting heart rate57 RHR 304 arrhythmias
Age at first birth58 AFB 45 education and development disorders
College59 COL 12
Education years60 EY 554
Subjective well-being53 SWB 9 positive mood disorders
Body fat percentage61 BFP 22 body mass disorders
Body mass index62 BMI 231
Childhood BMI63 CBMI 49
Leptin (adjusted for BMI)64 LEPB 5
Leptin (not adjusted for BMI)64 LEP 0
Waist-to-hip ratio65 WHR 74
This table lists the phenotypically matched pairs of complex traits (n ¼ 62) and groups of Mendelian disorders (n ¼ 20) examined in our study. More details on
these traits, including mean GWAS sample size, number of significant GWAS loci reported from original GWAS publications, and number of significant GWAS
SNPs, are included in Table S1. GWAS genes for each complex trait were identified by the mapping approach described in the Material and Methods.phenotype-specific Mendelian disorder gene sets and clinical
phenotype terms used in Table S2.
A comparison of all phenotype-specificMendelian disorder gene
sets revealed a high degree of overlap among the gene sets for clin-
ically related Mendelian phenotypes (Figure S1). Accordingly, we
clustered gene sets on the basis of pairwise overlap and intersected
gene sets clustering together by visual inspection at a hierarchical
clustering threshold to create a single gene set for the representa-
tive group of Mendelian disorders. Each complex trait was thus
matched with the single Mendelian disorder category in which
the original specific Mendelian disorder gene set clustered, which
ultimately best exemplified the phenotype.
Because of the systemic and pleiotropic nature of complex traits,
some complex traits could conceivably be phenotypically related
to more than one Mendelian disorder gene set. For example, we
generated theMendelian disorder gene set for SLE by using clinical
keywords for both the driving immunological event and the clin-
ical manifestations associated with SLE autoimmunity across a
large number of organ systems (kidney, brain, skin, pleura, joints,
etc.), such as ‘‘anemia.’’ Although the substantial contribution of
Mendelian disorder genes related to anemia resulted in SLE pairing
with the ‘‘hematological disorders’’ group, the immunological
component of SLE is central to the disease. Thus, we identified
immune dysregulation as a ‘‘relevant phenotype’’ for SLE and de-noted it as such in Figure 2 and Table 2 (the same occurred with
other traits).
After combining similar gene sets, we were left with 20 non-
disjoint phenotype-specific Mendelian disorder gene sets with
an average of 375 genes per set; we include a description of each
cluster in Table S3.Complex-Trait Gene Sets
We downloaded publicly available summary statistics (per-allele
SNP effect sizes, or log odds ratios [OR] for case-control traits,
with standard errors69) for large-scaleGWASs of 62 traits66 (Tables 1
and S1; average n ¼ 83,170, minimum n ¼ 10,610, maximum
n ¼ 298,420; some GWASs were imputed with the 1000 Genomes
Project as a reference panel by their respective consortia, whereas
otherswere not). For each trait, we identified a gene set bymapping
each autosomal genome-wide-significant SNP (p< 53 108) to the
closest up- anddownstreamprotein-coding genes as definedabove,
resulting in a total of 62 non-disjoint GWAS gene sets. Because
GWAS regions often contain multiple genome-wide-significant
SNPs and the relevant gene might not lie adjacent to the lead SNP
in a region,70,71 we defined GWAS gene sets by mapping genes
with respect to every genome-wide-significant SNP rather than
only the index GWAS SNPs at each genomic risk region.
Table 2. Overlap between GWAS Genes and Phenotypically Matched Mendelian Disorder Genes
Complex Trait
(No. of Genes)
Matched or Related Mendelian




Pair (CI) Raw p Value
Average OR for
Unmatched Pairs (CI)
AMD (215) monogenic AMD (104) 9 7.99 (3.50, 16.11) 4.94 3 106 1.69 (1.21, 2.16)
immune dysregulation (550) 17 2.73 (1.55, 4.52) 4.13 3 104
BFP (22) body mass disorders (128) 3 22.14 (4.14, 76.70) 5.15 3 104 2.63 (0.75, 4.51)
monogenic diabetes (182) 3 15.42 (2.90, 53.04) 1.43 3 103
BW (179) body mass disorders (128) 6 4.94 (1.76, 11.29) 1.93 3 103 1.93 (1.48, 2.37)
monogenic diabetes (182) 7 4.03 (1.57, 8.66) 2.56 3 103
CAD (132) cardiovascular disease (598) 13 3.17 (1.63, 5.67) 5.36 3 104 2.13 (1.65, 2.61)
insulin disorders (623) 13 3.04 (1.56, 5.43) 7.83 3 104
CBMI (49) body mass disorders (128) 5 16.18 (4.92, 41.63) 2.71 3 105 1.55 (1.13, 1.97)
insulin disorders (623) 7 4.61 (1.74, 10.41) 1.54 3 103
CD (239) immune dysregulation (550) 23 3.42 (2.10, 5.32) 1.70 3 106 2.09 (0.39, 4.58)
EY (554) positive mood disorders (69) 9 4.70 (2.04, 9.59) 2.88 3 104 0.94 (0.81, 1.07)
monogenic autism (111) 10 3.10 (1.44, 5.98) 2.54 3 103
psychiatric disease (264) 19 2.45 (1.44, 3.95) 8.96 3 104
FN (58) bone and uric acid disorders (220) 5 7.64 (2.36, 19.24) 7.61 3 104 3.79 (2.36, 5.22)
HB (89) disorders of platelet function (443) 12 6.21 (3.05, 11.59) 2.17 3 106 2.38 (1.68, 3.09)
hematologic disorders (551) 10 3.99 (1.83, 7.79) 4.42 3 104
HDL (464) body mass disorders (128) 12 3.92 (1.95, 7.17) 1.39 3 104 1.18 (1.00, 1.37)
monogenic diabetes (182) 15 3.41 (1.85, 5.85) 9.36 3 105
cardiovascular disease (598) 31 2.10 (1.40, 3.06) 3.45 3 104
HGT (2361) female reproductive disorders (288) 61 1.76 (1.30, 2.36) 2.18 3 104 1.31 (1.19, 1.42)
growth defects (723) 126 1.39 (1.13, 1.70) 1.43 3 103
IBD (368) immune dysregulation (550) 34 3.32 (2.23, 4.79) 1.58 3 108 1.38 (1.10, 1.66)
LDL (370) cardiovascular disease (598) 31 2.70 (1.79, 3.95) 3.45 3 106 1.66 (1.24, 2.08)
mature-onset diabetes of the young (561) 24 2.17 (1.36, 3.32) 8.54 3 104
LS (67) bone and uric acid disorders (220) 6 8.00 (2.80, 18.72) 1.83 3 104 2.53 (1.98, 3.08)
MCH (164) hematologic disorders (551) 15 3.19 (1.73, 5.48) 1.92 3 104 1.64 (1.16, 2.11)
MCV (180) hematologic disorders (551) 20 4.00 (2.36, 6.44) 8.90 3 107 1.61 (1.18, 2.04)
MNR (207) body mass disorders (128) 7 5.02 (1.95, 10.86) 7.76 3 104 1.03 (0.78, 1.27)
PBC (149) immune dysregulation (550) 13 3.03 (1.56, 5.40) 7.77 3 104 1.07 (0.76, 1.38)
PCV (53) disorders of platelet function (443) 10 9.24 (4.11, 18.83) 6.50 3 107 4.04 (2.22, 5.87)
arrhythmias (275) 5 6.70 (2.07, 16.94) 1.36 3 103
hematologic disorders (551) 8 5.60 (2.27, 12.08) 2.17 3 104
cardiovascular disease (598) 7 4.39 (1.66, 9.84) 1.94 3 103
PLT (134) disorders of platelet function (443) 12 3.91 (1.95, 7.15) 1.40 3 104 1.42 (0.98, 1.87)
RA (297) immune dysregulation (550) 25 2.95 (1.86, 4.50) 6.80 3 106 0.83 (0.65, 1.01)
RBC (107) hematologic disorders (551) 14 4.78 (2.50, 8.50) 5.82 3 106 2.76 (2.20, 3.33)
cardiovascular disease (598) 13 4.02 (2.05, 7.26) 6.49 3 105
RHR (304) arrhythmias (275) 17 3.93 (2.23, 6.53) 5.87 3 106 1.29 (0.95, 1.64)
cardiovascular disease (598) 26 2.75 (1.75, 4.16) 1.47 3 105




Matched or Related Mendelian




Pair (CI) Raw p Value
Average OR for
Unmatched Pairs (CI)
SCZ (479) positive mood disorders (69) 9 5.47 (2.37, 11.19) 9.71 3 105 1.11 (0.94, 1.28)
SLE (286) immune dysregulation (550) 24 2.94 (1.83, 4.52) 1.09 3 105 1.41 (1.10, 1.72)
T2D (28) body mass disorders (128) 4 23.55 (5.85, 69.99) 4.67 3 105 2.43 (1.57, 3.30)
monogenic diabetes (182) 3 11.72 (2.24, 38.93) 2.90 3 103
TC (500) cardiovascular disease (598) 38 2.44 (1.69, 3.45) 3.46 3 106 1.40 (1.10, 1.70)
TG (354) body mass disorders (128) 9 3.77 (1.67, 7.49) 1.10 3 103 1.26 (1.01, 1.51)
monogenic diabetes (182) 12 3.54 (1.78, 6.43) 3.10 3 104
cardiovascular disease (598) 25 2.22 (1.41, 3.38) 5.06 3 104
UC (202) immune dysregulation (550) 21 3.72 (2.23, 5.92) 1.39 3 106 1.45 (1.12, 1.78)
WHR (74) insulin disorders (623) 9 3.83 (1.67, 7.78) 1.13 3 103 2.37 (1.71, 3.04)
For each pair of complex trait andMendelian disorder, Fisher’s exact test was used to quantify the enrichment of shared genes with an OR and p value (seeMaterial
and Methods). Pairs with significant enrichment passed the cutoff of FDR< 5% at p< 0.00310. This table lists pairs of complex traits and phenotypically matched
or relatedMendelian disorders with significant overlap. For comparison, the average OR and 95%CI for pairings of each complex trait with all unrelatedMendelian
disorder gene sets are included.Quantifying Overlap between Complex Traits and
Mendelian Disorders
For each pair of complex trait and Mendelian disorder, we
compared the GWAS gene set and phenotype-specific Mendelian
disorder gene set with a 2 3 2 contingency table (indicating the
counts of gene membership in the GWAS gene set only, in the
Mendelian disorder gene set only, in both, or in neither) whereby
the set of autosomal protein-coding genes (n ¼ 17,695) repre-
sented the total sample. We used Fisher’s exact test72 to determine
significance. We assessed phenotype specificity of overlap signifi-
cance by comparing the GWAS gene sets for each complex trait
(n ¼ 62) with all phenotype-specific Mendelian disorder gene
sets (n ¼ 20), a total of 1,240 pairs. Significance was assessed at a
false-discovery rate (FDR) threshold < 5% (p < 0.00310).
To assess the robustness and stability of our SNP-gene mapping
approach for complex traits, we performed an overlap quantifica-
tion between phenotype-specific Mendelian disorder genes and
GWAS gene sets derived from three additional SNP-gene mapping
methods: mapping each genome-wide-significant SNP to all
genes within a 50 Mb window, mapping each genome-wide-sig-
nificant SNP to all genes within a 500 Mb window, and mapping
all SNPs in the credible set to the closest two genes. Comparison
of the ORs produced by Fisher’s exact test demonstrated no major
difference in outcomes from different mapping methods (Table
S4); thus, we found that even more conservative gene sets, such
as the GWAS gene sets derived from the credible set for each
complex trait, still demonstrate the pattern of trait-specific
enrichment.
Estimating Enrichment of GWAS SNP Association Signal
We created genomic annotations to capture the regions spanning
50 kb upstream through 50 kb downstream of gene bodies for four
categories of genes: all protein-coding genes (n¼ 17,695), all Men-
delian disorder genes (n ¼ 3,446), all LoF-intolerant genes
(n ¼ 2,978), and the phenotype-specific Mendelian disorder
gene sets (average n ¼ 609). For each pair of complex trait and
gene category, we computed enrichment of GWAS signal within
category c with respect to the set of all protein-coding genes




















Here, Nc is the number of genes in category c, Mj is the number of
SNPs within 50 kb of gene j, Zi is the GWAS effect size of SNP i
divided by the standard error, and Np is the total number of pro-
tein-coding genes. Thus, ac is the enrichment of the average SNP
effect size (Z2) per gene in category c (compared with the average
Z2 for any protein-coding gene). The percent increase in average
SNP effect size per gene for category c, or (ac  1) 3 100, is shown
in Figure 3. We performed similar comparisons for median SNP ef-
fect size per gene for category c and maximum SNP effect size per
gene for category c (Table S5).
To ensure that this signal was not driven by linkage disequilib-
rium (LD), minor allele frequency (MAF), or average gene length
per category, we compared these three properties across the gene
categories for each complex trait.We calculated LD scores73 reflect-
ing the amount of LD tagged by each SNP in the HapMap 3 refer-
ence panel; then, for each gene category, we averaged the LD
scores of SNPs falling within 50 kb of each gene. We performed
similar analyses to examine average MAF per gene and average
gene length per category across each complex trait (Table S6).
For comparison, we additionally performed a permutation test
by drawing 100 sets of random genes for each Mendelian disorder
gene set (matched for number and length of genes) and
computing the average effect size per gene for each phenotypically
matched complex trait across all 100 random sets.Putative Causal Mechanisms at GWAS Risk Regions
We performed statistical fine-mapping of the genome-wide-signif-
icant regions (p < 5 3 108) for each GWAS by using fgwas74 with
no functional annotations and default parameter settings. For
eachGWAS, we constructed a 95% credible set (defined as themin-
imum set of SNPs where 95% of the probability of causation at a
region is accumulated) for each region of 500 SNPs containing a
significant GWAS association. We achieved this by adding SNPs
one at a time with a decreasing posterior probability of causation
Figure 1. GWAS Gene Sets and Phenotype-Specific Mendelian Disorder Gene Sets
For each complex trait (e.g., height), we first identified matched Mendelian phenotypes (e.g., undergrowth and short stature; Table S2).
Using publicly available GWAS data, we defined the ‘‘GWAS genes’’ for a given complex trait to be the closest upstream and closest down-
stream protein-coding genes for every genome-wide-significant variant in the GWAS. We selected phenotype-matched Mendelian dis-
order genes by first identifying Mendelian disorders expressing any of the matched Mendelian phenotypes and then identifying all
genes linked to any of those disorders.(posterior probability of association for the SNP, conditioned on
there being an association in the region) until a cumulative 95%
probability of causation was reached.
Identification of Candidate Regulatory Variants
We intersected credible sets for each complex trait with genomic
regions 1 kb upstream of each phenotypically relevant Mende-
lian disorder gene to identify SNPs localizing at the TSS. To iden-
tify genes whose expression the GWAS SNPs might regulate, we
queried the UCSC GTEx Combined eQTL Track (version 2017-
10-25) and filtered by SNP rsID. This table describes all gene-tis-
sue pairs where a SNP has evidence of regulatory function. We
restricted results to phenotype-matched Mendelian genes whose
promoter contained a genome-wide-significant SNP in our
GWAS fine-mapped results. To identify candidate regulatory var-
iants interacting with promoters of phenotype-matched Mende-
lian disorder genes, we used interactions from promoter capture
Hi-C in human primary white adipocytes66 for each complex
trait and filtered interactions to pairs of interacting regions
where at least one region contained a promoter of a pheno-
type-specific Mendelian disorder gene. We then intersected
interaction pairs for each of these regions with credible sets for
each complex trait to identify credible SNPs interacting with re-
gions containing promoters of phenotype-specific Mendelian
disorder genes.
Estimating the Enrichment of SNP Heritability of
Complex Traits within Mendelian Disorder Gene-Set
Annotations
We used stratified LD score regression (s-LDSC)75 to estimate the
enrichment of SNP heritability of 47 complex traits and diseases
within each of 20 Mendelian disorder gene-set annotations corre-
sponding to the regions spanning 50 kb upstream through 50 kb
downstream of gene bodies for each Mendelian disorder gene
set. Of the 62 total GWAS traits analyzed in this study, the 47 com-
plex traits and diseases are a subset that meet the criteria for
running s-LDSC (i.e., the GWAS did not use custom genotyping
arrays). The annotation value for SNP i and gene set k is definedas aik ¼ 1 if SNP i is within 50 kb upstream or 50 kb downstream
of any of the gene bodies in gene set k and aik ¼ 0 otherwise. For
each of the 20 annotations, we computed LD scores within 1 cM
blocks with default parameters and LD estimated from the Euro-
pean individuals in the 1000 Genomes Phase 3 reference panel.
For each GWAS-annotation pair, we ran s-LDSC by using the rec-
ommended ‘‘baseline model’’75 as covariates in the regression for
a total of 53 annotations per run (52 ‘‘baseline’’ annotations plus
the gene-set annotation of interest).Results
GWAS Risk Genes Show Specific, Significant Overlap
with Phenotypically Matched Mendelian Disorder
Genes
We first sought to examine the degree of overlap between
phenotype-matched Mendelian disorder genes with risk
genes for complex traits as identified through GWASs.
For each complex trait, we identified corresponding Men-
delian forms, often as familial forms or rare phenotypic
extremes, and curated Mendelian disorder gene sets
composed of Mendelian disorder genes linked to those
specific phenotypes from OMIM (see Material and
Methods and Figure 1). We combined similar Mendelian
disorder gene sets to create one gene set for the represen-
tative Mendelian disorder(s) (for a total of 20 Mendelian
disorder gene sets). We separately ascertained GWAS gene
sets for each complex trait by identifying the closest up-
and downstream genes to each GWAS SNP meeting
genome-wide significance (see Material and Methods
and Figure 1). Overlap between each phenotype-specific
Mendelian disorder gene set (n ¼ 20) and each GWAS
gene set (n ¼ 62) was assessed by Fisher’s exact test for
a total of 1,240 comparisons (Tables 1 and S7). We hy-
pothesized that GWAS gene sets would have a specific
Figure 2. Overlap between GWAS Genes and Mendelian Disorder Genes Demonstrates Trait Specificity
Significant overlaps from phenotypically matched pairs of complex traits and Mendelian disorders (blue) and pairs with unrelated phe-
notypes (gray) are shown. Phenotypically matched pairs are subdivided into pairs with perfectly matched phenotypes (light blue) and
pairs with related phenotypes (dark blue). Complex traits andMendelian disorders with no significant overlaps are excluded here; results
from all traits are presented in Figure S2. We assessed significance by controlling for FDR < 5% at p < 0.00310.significant enrichment of Mendelian disorder genes for
perfectly matched Mendelian disorders (as identified in
Table 1; 62 of the 1,240 comparisons) or related Mende-
lian disorders (an additional 30 of the 1,240 compari-
sons; 92 of 1,240 total) but no enrichment for unrelated
Mendelian disorders (the remaining 1,148 of 1,240 com-
parisons). Among all 1,240 pairs of complex and Mende-
lian disorder gene sets assessed, we identified 77 pairs
with significant overlap crossing an FDR < 5% cutoff at
p < 0.00310 (Figure 2). An examination of the log ORs
for each overlap comparison revealed more extreme en-
richments among phenotypically matched pairs than
among phenotypically unmatched pairs (Table 2), which
is consistent with our hypothesis. 50 out of the 77 signif-
icantly overlapping pairs showed perfectly matching
phenotypes (as defined in Table 1; see Material and
Methods) or reflected known shared biology (identified
in dark blue within Figure 2). Specifically, in many of
these pairs, monogenic forms of the complex trait have
been well established in the genetics literature; examples
include age-related macular degeneration and cholesterol
traits (high-density lipoprotein [HDL], low-density lipo-
protein [LDL], total cholesterol [TC], and triglycerides
[TG]).7,76–79 We confirmed significant enrichment be-
tween many of these previously reported pairs; for
example, we found significant enrichment between the
complex and monogenic forms of height80 (OR ¼ 1.39,
p ¼ 1.43 3 103) and between HDL and Mendelian forms
of cardiovascular disease81 (OR ¼ 2.10, p ¼ 3.45 3 104).We also identified previously unreported enrichments;
for example, we found a strong enrichment between
inflammatory bowel disease and Mendelian forms of im-
mune dysregulation (OR ¼ 3.32, p ¼ 1.58 3 108) and be-
tween hemoglobin and Mendelian hematologic disorders
(OR ¼ 3.99, p ¼ 4.42 3 10 4). The remaining 27 pairs
with significant overlap suggested shared biological
mechanisms yet to be established between complex traits
and Mendelian disorders (Table 3). For example, we
observed an enrichment between height and renal disor-
ders (OR ¼ 1.48, p ¼ 3.75 3 105) and enrichment be-
tween Crohn disease and mature-onset diabetes of the
young (OR ¼ 2.69, p ¼ 2.32 3 104). Strikingly, a higher
proportion of phenotypically matched or related pairs
(n ¼ 50 of 92 [54%]) than phenotypically unmatched
pairs (n ¼ 27 of 1,148 [2%]) demonstrated significant
overlap, consistent with our hypothesis of a phenotype-
specific enrichment pattern (Table S7 and Figure S2).
To investigate whether intra-chromosomal proximal
clustering of genes with similar functionality was con-
founding our results, we pruned our dataset of all protein-
coding genes to include only one gene per 33.2 kb window
across the genome (determined by the average distance to
the next closest gene in our dataset) and re-computed over-
lapORs. The results were highly similar to those of our orig-
inal approach (Pearson r ¼ 0.96). Moreover, we found the
average distance to the next closest gene among the sets
of genes shared by a phenotypically matched pair of com-
plex trait and Mendelian disorder to be 21.1 Mb (Table S8).
Table 3. Instances of Significant Overlap between GWAS Genes and Unrelated Mendelian Disorder Genes
Complex Trait
(No. of Genes)
Matched or Related Mendelian
Disorder (No. of Genes)
Shared




ALZ (58) immune dysregulation (550) 7 4.32 (1.65, 9.62) 2.06 3 103 1.95 (1.36, 2.53)
AMD (215) microalbumin disorders (159) 8 4.43 (1.86, 9.13) 7.37 3 104 1.59 (1.03, 2.15)
BW (179) mature-onset diabetes of the young (561) 16 3.06 (1.69, 5.16) 1.91 3 104 2.35 (1.94, 2.75)
immune dysregulation (550) 14 2.69 (1.43, 4.68) 1.44 3 103
cardiovascular disease (598) 14 2.46 (1.31, 4.28) 3.10 3 103
CAD (132) neurologic disease (222) 7 4.52 (1.76, 9.75) 1.39 3 103 2.34 (1.83, 2.86)
CD (239) bone and uric acid disorders (220) 9 3.20 (1.42, 6.29) 3.10 3 103 2.09 (0.39, 4.58)
mature-onset diabetes of the young (561) 19 2.69 (1.58, 4.35) 2.32 3 104
renal disorders (838) 23 2.17 (1.34, 3.37) 1.13 3 103
CEL (34) disorders of platelet function (443) 5 6.78 (2.04, 17.83) 1.47 3 103 1.90 (1.28, 2.52)
FN (58) positive mood disorders (69) 3 14.51 (2.83, 46.53) 1.50 3 103 3.79 (2.36, 5.22)
HGT (2361) renal disorders (838) 153 1.48 (1.23, 1.78) 3.75 3 105 1.31 (1.19, 1.42)
IBD (368) mature-onset diabetes of the young (561) 30 2.81 (1.85, 4.13) 2.40 3 106 1.38 (1.10, 1.66)
LDL (370) hematologic disorders (551) 25 2.31 (1.46, 3.51) 3.50 3 104 1.66 (1.24, 2.08)
LEPB (5) female reproductive disorders (288) 2 40.52 (3.37, 353.67) 2.56 3 103 10.83 (3.75, 17.91)
MCH (164) bone and uric acid disorders (220) 8 4.19 (1.75, 8.61) 1.05 3 103 1.65 (1.15, 2.16)
insulin disorders (623) 15 2.80 (1.52, 4.81) 6.99 3 104
MCV (180) bone and uric acid disorders (220) 8 3.80 (1.59, 7.79) 1.89 3 103 1.74 (1.25, 2.22)
PCV (53) positive mood disorders (69) 3 15.97 (3.11, 51.37) 1.16 3 103 4.04 (2.22, 5.87)
PLT (134) cardiovascular disease (598) 12 2.85 (1.42, 5.20) 1.97 3 103 1.42 (0.98, 1.87)
RBC (107) disorders of platelet function (443) 12 5.03 (2.49, 9.29) 1.51 3 105 2.90 (2.13, 3.67)
renal disorders (838) 18 4.14 (2.33, 6.96) 2.60 3 106
SLE (286) mature-onset diabetes of the young (561) 22 2.61 (1.59, 4.07) 1.24 3 104 1.59 (1.24, 1.94)
TC (500) hematologic disorders (551) 32 2.20 (1.47, 3.18) 1.18 3 104 1.35 (1.05, 1.66)
disorders of platelet function (443) 25 2.11 (1.34, 3.20) 1.13 3 103
UC (202) mature-onset diabetes of the young (561) 19 3.25 (1.90, 5.27) 2.44 3 105 1.41 (1.05, 1.77)
WHR (74) disorders of platelet function (443) 7 4.12 (1.59, 9.03) 2.50 3 103 2.38 (1.58, 3.18)
As in Table 2, Fisher’s exact test was used to quantify the enrichment of shared genes between complex traits and Mendelian disorders with an OR and p value
(see Material and Methods). Pairs with significant enrichment passed the cutoff of FDR < 5% at p < 0.00310. This table lists pairs of complex traits and pheno-
typically unrelated Mendelian disorders that demonstrated significant overlap. For comparison, the average OR and 95% CI for pairings of each complex trait with
all remaining unrelated Mendelian disorder gene sets are included.SNPs near Phenotypically Matched Mendelian Disorder
Genes Show Increased Effect Size on Complex Traits
Because Mendelian disorder genes are linked with severe
biological effects when either one or both alleles are dis-
rupted, dysregulation of the gene through changes in
expression or other mechanisms might have a more signif-
icant effect than dysregulation of another protein-coding
gene not linked to any Mendelian disorders. We hypothe-
sized that SNPs near these phenotype-specific Mendelian
disorder genes have further increased effects on complex
traits as a result of the increased biological relevance of
these gene categories. From the publicly available GWAS
summary statistics for each complex trait, we computedthe average GWAS effect sizes of SNPs falling within each
protein-coding gene and compared the average effect sizes
per gene across all Mendelian disorder genes and across
phenotypically relevantMendelian disorder genes (seeMa-
terial and Methods). Across complex traits, we found an
increased average effect size per gene for all Mendelian dis-
order genes and a further increased average effect size per
gene for phenotypically relevant Mendelian disorder genes
(Figure 3 and Table S5). This suggests that the genomic
regions containing the most biologically relevant genes
for each trait contribute most significantly to the biology
of complex traits. We also confirmed that LoF-intolerant
genes (as defined by ExAC’s pLI score > 0.9; see Material
Figure 3. Effect Sizes for SNPs on Com-
plex Traits from GWASs Are Higher for
LoF-Intolerant Genes and for Phenotypi-
cally Relevant Mendelian Disorder Genes
The increase in average SNP effect size per
gene across gene categories, as compared
with all protein-coding genes (dashed
line), is shown. We averaged effect size
(Z2) across all SNPs falling within 50 kb of
a gene to obtain an average SNP effect
size per gene and averaged across all genes
in each category (all protein-coding genes,
all Mendelian disorder genes, all LoF-intol-
erant genes, and all phenotypically rele-
vant Mendelian disorder genes for each
trait). We normalized these averages to
the average SNP effect per gene for any pro-
tein-coding genes. The boxplots represent
the distribution of increases in average ef-
fect size per gene across all traits, and
notches designate the confidence intervals
(CIs). From left to right, CIs read (0.07,
1.24), (1.47, 3.54), and (5.88, 12.19).and Methods) demonstrate a higher average effect size
across most complex traits examined.68 Given the extreme
intolerance of deleterious mutations in these genes, it is
possible that LoF-intolerant genes are linked with embry-
onically lethal mutant phenotypes and are thus undiscov-
ered as Mendelian disorder genes at this time.
We found no significant difference in LD or average MAF
between the SNPs within each category and the SNPs
within all protein-coding genes (Table S6), suggesting
that the observed signal is not driven by any of these po-
tential confounders. In particular, we found the average
LD tagged for all protein-coding genes to be 24.38 (95%
confidence interval [CI] ¼ (24.35, 24.42)); for none of the
other three gene classes did the CIs fall above the upper
bound, including the average across all Mendelian disorder
gene sets (24.10; 95% CI ¼ (23.47, 24.72)). Similarly, we
found the average MAF for all protein-coding genes to be
0.238 (95% CI ¼ (0.237, 0.239)); for none of the other
gene classes did the CIs fall below the lower bound,
including the average across all Mendelian disorder gene
sets (0.238; 95% CI ¼ (0.237, 0.240)). Details for each
gene set are included in Table S6. Of note, we did observe
an increase in average gene length across gene categories,
particularly between all protein-coding genes (159.94 kb;
95% CI ¼ (158.16 kb, 161.71 kb)) and the average across
all phenotype-specific Mendelian disorder gene sets
(177.87 kb; 95% CI ¼ (168.49 kb, 187.24 kb)) (Table S6).
To ensure that our findings of enriched GWAS signal in
these gene categories were not due to longer genes’ being
more likely to tag causal variation, we performed a permu-
tation test comparing the average effect size per gene for
phenotype-matched Mendelian disorder genes with the
same metric across 100 sets of random genes (matched
for number of genes and gene length) (Table S6). We found
no evidence that gene length confounded our results given
that across 58 of 62 complex traits, the average effect sizeper gene was higher for phenotype-matched Mendelian
disorder genes than for random genes of the same length.
Also of note, we did not find evidence of a pervasive
phenotype-specific enrichment of SNP heritability within
50 kb of Mendelian disorder genes (Table S9; see Material
and Methods). Thus, we can conclude that the average
GWAS effect size per gene for phenotypically relevant
Mendelian disorder genes is higher than that of all pro-
tein-coding genes, all Mendelian disorder genes, and LoF-
intolerant genes.
Examples of Credible SNPs for GWAS Regions near
Phenotypically Matched Mendelian Disorder Genes
We next sought to identify common non-coding variants
thatmight causally affect complex-trait phenotypes by dys-
regulating phenotypically relevant Mendelian disorder
genes. For each complex trait, we performed statistical
fine-mapping of significant GWAS regions to construct
95% credible sets for each region (see Material and
Methods) and identified SNPs from the credible set located
at the TSS of a gene from the phenotypically relevant Men-
deliandisorder gene set.We found a total of 786 credible-set
SNPs (out of approximately 3.5 million) localizing at the
TSS of a phenotypically relevant Mendelian disorder gene
(an average of 20 SNPs per trait for 38 traits where at least
one such SNPwas found; Tables S10 and S11).We identified
25 promising candidate SNPs (attaining genome-wide sig-
nificance in a GWAS) at TSSs that could be regulating the
proximal Mendelian disorder gene (Table 4). We further
examined the GTEx Portal to determine whether any of
these SNPs were also expression quantitative trail loci
(eQTLs) for the corresponding gene; we found 12 variants
to be significant eQTLs for the corresponding gene in at
least one tissue (Table 4). We highlight two examples: first,
we found a significantly associated SNP from the credible
set for coronary artery disease (rs1332327, Z ¼ 6.80) at the










PBC rs13239597 chr7: 128,695,982 9.85 TNPO3 (610032) – – –
HGT rs8028537 chr15: 89,345,946 9.33 ACAN (155760) – – –
HGT rs10853751 chr19: 41,903,219 8.71 BCKDHA (608348) – – –
CD rs59283234 chr5: 150,225,586 8.45 IRGM (608212) 0.042 6.733 whole blood
CD rs751627 chr5: 150,225,112 8.45 IRGM (608212) 0.042 6.733 whole blood
CD rs35707106 chr5: 150,225,376 8.33 IRGM (608212) 0.041 6.412 whole blood
HGT rs2298307 chr6: 80,816,295 8.28 BCKDHB (248611) – – –
HGT rs12386601 chr7: 92,157,885 8.20 PEX1 (602136) – – –
BMI rs17066842 chr18: 58,040,623 7.54 MC4R (155541) – – –
HGT rs12192268 chr6: 110,011,457 7.00 FIG4 (609390) – – –





RA rs13239597 chr7: 128,695,982 6.66 TNPO3 (610032) – – –
IBD rs59283234 chr5: 150,225,586 6.51 IRGM (608212) 0.042 6.733 whole blood
IBD rs751627 chr5: 150,225,112 6.51 IRGM (608212) 0.042 6.733 whole blood
HGT rs7592246 chr2: 219,926,220 6.45 IHH (600726) 0.056 6.199 brain cerebellum
IBD rs34005003 chr5: 150,225,198 6.43 IRGM (608212) 0.043 6.637 whole blood
IBD rs35707106 chr5: 150,225,376 6.33 IRGM (608212) 0.041 6.412 whole blood
MNR rs3775971 chr4: 104,641,919 6.20 TACR3 (162332) 0.019 8.588 lung
IBD rs27741 chr16: 28,504,180 6.11 CLN3 (607042) – – –
HGT rs4244808 chr11: 2,163,109 6.06 IGF2 (147470) – – –
RBC rs1010222 chr19: 13,048,607 5.96 CALR (109091) 17.142 6.851 lung
CD rs27741 chr16: 28,504,180 5.87 CLN3 (607042) – – –
HGT rs613924 chr11: 65,769,294 5.86 BANF1 (603811) – – –
AFB rs4845357 chr1: 153,896,211 5.78 GATAD2B (614998) 0.108 4.443 skin not exposed
HGT rs6591226 chr11: 66,675,989 5.52 PC (608786) – – –
GWAS SNPs from the credible set for each complex trait were intersected with TSS regions 1 kb upstream of phenotypically matched Mendelian disorder genes.
This table lists all genome-wide-significant SNPs (p < 5 3 108 from GWASs) with chromosomal location from all complex traits localizing at the TSS of a pheno-
typically matched Mendelian disorder gene.promoter of LIPA (MIM: 278000), a Mendelian disorder
gene linked toWolmandisease and cholesteryl ester storage
disease (both lysosomal acid lipase deficiencies [MIM:
278000]), which involve hypercholesterolemia and hyper-
triglyceridemia as part of cholesteryl ester- and triglycer-
ide-filled macrophage infiltration syndromes (Figure 4A).
Additional analyses identified rs1332327 (along with other
SNPs in LD with the variant) as a cis-eQTL for LIPA in the
METSIM adipose RNA-sequencing dataset (Table S13); this
finding is consistent with eQTL results reported in the
GTEx Portal for these SNPs and LIPA. Second, from the cred-
ible set for red blood cell count, we found a significantly
associated SNP (rs1010222, Z ¼ 5.97) at the promoter of
CALR (MIM: 109091), a Mendelian disorder gene linked tomyelofibrosis (MIM: 254450), which involves generalized
bone marrow fibrosis, reduced hemopoiesis, a lack
of hemophagocytosis, and myeloproliferative disease
(Figure 4B). In both cases, the putative causal SNP for the
complex trait lies immediately upstream of the TSS of the
phenotypically relevant Mendelian disorder gene, in addi-
tion to falling within regions containing regulatory epige-
netic marks.
Putative Causal SNPs for GWAS Regions Interacting with
Promoters of Phenotypically Relevant Mendelian
Disorder Genes
Functional genomic datasets, such as chromatin interac-
tions identified through Hi-C, can give us insight into
Figure 4. Candidate Regulatory SNPs Fall at TSSs and Long-Range Promoters of Phenotypically Relevant Mendelian Disorder Genes
(A and B) Shown here are two examples of putative causal SNPs localizing at a TSS of a phenotypically relevant Mendelian disorder gene.
(A) Putative causal SNP rs1332327, associated with coronary artery disease (Z ¼ 6.80), lies at the TSS of LIPA. (B) Putative causal SNP
rs1010222, associated with red blood cell count (Z ¼ 5.97), lies at the TSS of CALR.
(C and D) Shown here are two representations of chromatin interactions in white adipose tissue. (C) A cluster of SNPs from the credible
set of variants associated with BMI (Z score plotted in orange and blue) physically interacts with the promoter of a particular isoform of
CYP19A1. (D) A single SNP (rs758747) from the credible set, associated with BMI (Z ¼ 6.08), physically interacts with the promoter of a
distant gene, CREBBP.the functional interpretation of GWAS variants and how
they might regulate Mendelian disorder genes. Examina-
tion of chromatin interactions in human primary white
adipocytes66 revealed further candidate credible-set, meta-
bolic-trait SNPs physically interacting with promoters of
phenotypically relevant Mendelian disorder genes (Table
S12). Specifically, we report that a genome-wide-significant
SNP for BMI (rs758747, Z ¼ 6.08) physically interacts with
the promoter of CREBBP, a gene linked to Rubinstein-Taybi
syndrome 1 (MIM: 180849), in which obesity is one of the
syndromic features (Figure 4C). These interactions can also
identify the relevant isoforms of genes in disease. From the
credible set of variants associated with BMI, we identified a
cluster of SNPs that physically interact with the promoter
of a specific isoform of CYP19A1, a gene linked to aroma-
tase excess syndrome (MIM: 139300), which involves short
stature and excess fat storage in the chest (gynecomastia)
(Figure 4D). Although longer isoforms of CYP19A1 are by
default chosen to represent the gene, our data suggest
that the shorter isoform is likely to be more relevant in
obesity. Together, these results demonstrate examples of
GWAS variants localizing in regulatory regions for pheno-
typically relevant Mendelian disorder genes, consistentwith the hypothesis that low-effect common variants
contribute to complex traits by regulating genes known
to cause Mendelian disorders.Discussion
In this work, we used GWAS summary statistics from 62
complex traits and genes linked to specific phenotypes
within20Mendelianbroad disorders to quantify the shared
genetic basis of complex traits andMendelian disorders.We
identified a pervasive, specific enrichment of phenotypi-
cally matched and related Mendelian disorder genes in
GWAS regions for complex traits; we also identified some
pairs of complex traits and phenotypically unmatched
Mendelian disorders with significant enrichment. We
further found that phenotypically relevant Mendelian dis-
order genes are enriched with GWAS signal across complex
traits in comparison with all Mendelian disorder genes and
other protein-coding genes. Finally, we report examples of
putative causal SNPs for GWAS regions in potentially regu-
lating phenotypically relevant Mendelian disorder genes.
We conclude with four considerations about how our
results contribute to the understanding of genetic architec-
tures and biological mechanisms across complex traits and
Mendelian disorders.
First, our finding of a specific enrichment of phenotypi-
cally matched and related Mendelian disorder genes in
GWAS regions for complex traits suggests that, across com-
plex-trait architectures, many complex traits share a ge-
netic basis (and by extension, biological mechanisms)
with their Mendelian forms. This supports our hypothesis
that the shared genes contribute to both extreme and com-
mon genetic phenotypes and suggests an important role of
gene regulation by non-coding variants in complex traits.
However, we note that our findings are limited by the po-
wer of each GWAS to detect significant associations. As
GWASs become better powered, we anticipate being able
to identify phenotype-specific enrichments of Mendelian
disorder genes in GWAS regions for more complex traits.
Second, we identified a subset of pairs of complex traits
and Mendelian disorders that, despite having no known
shared biology, still demonstrated significant enrichment
of Mendelian disorder genes in GWAS regions. This subset
of pairs can offer us insight into the biological mechanisms
of complex traits andMendelian disorders. A high degree of
co-morbidity between complex traits andMendelian disor-
ders has been previously observed regardless of phenotype
similarity;24 these findings together suggest that many
complex traits and Mendelian disorders might also be
linkedby thepleiotropicproperties of theunderlyinggenes,
in addition to regulatorydifferences. These observations are
also consistent with amultigenic or oligogenic architecture
of human disease; the pervasive pleiotropic effects that are
seen across complex traits are consistent with the wide-
spread prevalence of multi-system, syndromic phenotypes
observed across a majority of Mendelian disorders. We
also confirm that LoF-intolerant genes harbor an enrich-
ment of GWAS signal;68 because genes with pLI > 0.9
exhibit extreme intolerance of deleterious mutation, it is
possible that these genes demonstrate embryonically lethal
mutant phenotypes and are thus undiscovered as Mende-
liandisorder genes at this time.Ourfindings provide further
motivation to explore phenotypic consequences of muta-
tions in LoF-intolerant genes (particularly those enriched
with GWAS signal for a particular complex trait) for pheno-
typically relevant Mendelian disorders.
Third, linking Mendelian disorder genes with complex
traits canhelpwith characterization of the genetic architec-
ture of complex traits—specifically with genes and
pathways that can be functionally characterized for the
identification of molecular mechanisms.7 Identifying
causal variants from large-scale GWASs is particularly chal-
lenging given that most GWAS loci lie in non-coding re-
gions of the genome; although thousands of genomic loci
have been significantly associated with specific diseases,
few casual SNPs have been functionally verified.82,83
Many approaches have been used to tie a particular variant
to a relevant gene or genes,84–86 including newer methods
that directly link gene expression to a trait (e.g., transcrip-tome-wide association studies70 and PrediXcan87); we
have found that leveraging GWAS findings with functional
data to identify candidate regulatoryvariants forMendelian
disorder genes can potentially lead to better interpretation
of relevant genes and isoforms. Here, we demonstrate the
heterogeneityofmechanismspotentiallyunderlying causal
variationby showing roles for TSSpromoter regionsofMen-
deliandisorder genes and long-range interactions involving
significant GWAS regions. We expand on recent work
showing that BMI-associated variants interact with genes
in GWAS regions to demonstrate similar findings for Men-
delian disorder genes.66 With the appropriate functional
data from relevant tissues and cell types, this phenotype-
driven approach can identify relevant candidate regulatory
variants and their targets. Further, from the perspective of
monogenic diseases, identifying common variants that
might modify the expressivity of phenotypes can provide
insights into gene function in addition to putative drug tar-
gets. Many drugs approved by the FDA and developed by
pharmaceutical companies are targeted toward the treat-
mentof complex traits anddiseases; by identifyingunderly-
ing links between Mendelian disorders and complex traits
through their effects on the samebiological genes andpath-
ways, we can systematically and rationally target existing
drugs for complex traits and diseases toward those with
rareMendelian disorders that largely do not have any ratio-
nally targeted treatments.88–90
Fourth and finally, we note that our approach of exam-
ining traits and disorders at the component-phenotype
level offers us valuable resolution into the specificpathways
involved in the overall trait or disorder. In clinical genetics,
genome-wide sequencinghas expanded the clinical pheno-
typic spectrum associatedwith a gene91,92 through identifi-
cation of pleiotropic effects due to mutations in specific
protein domains.93,94 These advances have detected a ge-
netic predisposition for diseases previously considered to
be due to environment13 and uncovered variable pene-
trance for genetic mutations previously thought to be suffi-
cient to cause disease. Furthermore, the findings from clin-
ical genome-wide sequencing have suggested that genetic
background influences the phenotypic variability ofmono-
genic diseases.95,96 The phenotypic characterizations of
Mendelian syndromes are deconstructed by expert clinical
geneticists into component phenotypes, labeled by stan-
dardized clinical terms that identify both the primary phe-
notypes and phenotypes that have variable penetrance and
expressivity.97 Recentwork has demonstrated that incorpo-
rating such dense phenotype information into ranking pu-
tative disease-causing genetic mutations improves diag-
nostic rates in clinical exome sequencing tests;98,99 using
component Mendelian phenotypes to identify Mendelian
disorders thatmight be phenotypically relevant to a variety
of complex traits can be similarly impactful in identifying
biological pathways for complex traits. Ultimately, identifi-
cation of GWAS-significant regions with biologically rele-
vant genes and pathways will enable effective utilization
of GWAS data in medical settings.
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